These are top 10 stocks traded on the Robinhood UK platform in July
On Thursday, Rosenblatt Securities increased its price target for Universal Technical Institute (NYSE:UTI) shares to $36 from the previous $30, while reaffirming a Buy rating on the stock. The firm’s analysts cited UTI’s impressive performance, which includes robust corporate partnerships and successful student outcomes, as key drivers for the raised target. The company’s stock has demonstrated remarkable momentum, with a 92.74% return over the past year and currently trades near its 52-week high of $29.04.InvestingPro data reveals that UTI maintains a "GREAT" overall financial health score of 3.23, with particularly strong momentum metrics. Subscribers can access 8 additional ProTips and a comprehensive Pro Research Report for deeper insights into UTI’s performance.
According to Rosenblatt, UTI’s recent financial results outperformed expectations, prompting the firm to revise its estimates upward. The analyst, Steve Frankel, highlighted the company’s effective strategies and the high return on investment (ROI) that UTI’s schools offer to students as fundamental factors contributing to the company’s success. This is reflected in UTI’s strong financial metrics, including a 20.63% revenue growth and an impressive 54.68% gross profit margin. Frankel remarked on the importance of UTI’s role in addressing the increasing skills gap in the United States and pointed to the company’s expansion initiatives as indicators of continued growth potential.
The new price target of $36 is based on a 15 times enterprise value to calendar year 2026 EBITDA (earnings before interest, taxes, depreciation, and amortization) multiple. This valuation represents a premium compared to UTI’s peers, with the company currently trading at a P/E ratio of 36.25 and generating $88.42 million in EBITDA. According to InvestingPro’s Fair Value analysis, the stock appears to be trading above its intrinsic value. Rosenblatt justifies the premium valuation with the management team’s proven track record of strong performance and strategic focus on driving positive student outcomes.
Universal Technical Institute’s strong corporate partnerships are seen as a significant advantage in the competitive educational landscape. These partnerships contribute to the high ROI for students, as UTI’s programs are closely aligned with industry needs, enhancing employability upon graduation.
Rosenblatt’s decision to maintain a Buy rating reflects the firm’s confidence in Universal Technical Institute’s future performance and its strategic position within the education sector. The increased price target suggests that Rosenblatt anticipates further upside for UTI shares, based on the company’s solid execution and strategic initiatives.
In other recent news, Universal Technical Institute (UTI) has made significant strides in its financial performance and strategic partnerships. The company reported a robust fiscal year 2024, with a 21% increase in revenue to $733 million and a net income of $42 million. UTI also witnessed a 10% rise in full-time active students and a 60% improvement in adjusted EBITDA, reaching $103 million. The company is projecting revenue in the range of $800-$815 million for fiscal 2025.
In addition to its strong financial performance, UTI has expanded its Manufacturer Specific Advanced Training (MSAT) offerings by including Tesla (NASDAQ:TSLA)’s START Collision Repair program, which is set to commence at its Long Beach campus in Spring 2025. This partnership with Tesla underscores UTI’s commitment to innovation and readiness for the evolving automotive landscape.
On the analyst front, Rosenblatt Securities increased its price target for UTI to $30.00, up from the previous $22.00, maintaining a Buy rating on the stock. This decision follows UTI’s impressive performance in a recent quarter, bolstered by significant industry trends. These recent developments highlight UTI’s strategic positioning in the market and its ability to meet the increasing demand for qualified workers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.